Celltrion Inc., a leading South Korean biopharmaceutical company, has commenced the initial shipment of its novel subcutaneous injection formulation for autoimmune disease treatment, Remsima SC, branded as Zymfentra in the U.S. This marks a pivotal step in its expansion into the American healthcare sector. The first of three batches was shipped on February 11, 2021, with the product anticipated to be available by mid-March, providing a critical new therapeutic option for individuals with autoimmune conditions.
This strategic initiative is part of Celltrion’s comprehensive plan to establish a significant presence in the U.S. pharmaceutical market. Zymfentra, a subcutaneous version of the intravenous Remsima (infliximab), received FDA approval in October 2020, highlighting its quality, safety, and efficacy.
Having received approval in over 50 countries, including Europe and Canada, Zymfentra’s global rollout underscores its therapeutic value and broad international acceptance. Its U.S. launch not only broadens treatment possibilities for autoimmune disease patients but also underscores Celltrion’s commitment to enhancing access to innovative biologic therapies, reinforcing its status in the global biopharmaceutical industry.
